VivoSim Labs (NASDAQ:VIVS – Get Free Report) and Quantum-Si (NASDAQ:QSI – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends, earnings, profitability, risk and institutional ownership.
Earnings and Valuation
This table compares VivoSim Labs and Quantum-Si”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| VivoSim Labs | $130,000.00 | 28.97 | -$13.84 million | ($4.47) | -0.05 |
| Quantum-Si | $2.44 million | 66.84 | -$101.34 million | ($0.46) | -1.62 |
Volatility & Risk
VivoSim Labs has a beta of 1.45, suggesting that its share price is 45% more volatile than the S&P 500. Comparatively, Quantum-Si has a beta of 3.25, suggesting that its share price is 225% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current ratings and recommmendations for VivoSim Labs and Quantum-Si, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| VivoSim Labs | 1 | 0 | 0 | 0 | 1.00 |
| Quantum-Si | 1 | 1 | 1 | 0 | 2.00 |
Quantum-Si has a consensus target price of $1.00, indicating a potential upside of 34.21%. Given Quantum-Si’s stronger consensus rating and higher probable upside, analysts plainly believe Quantum-Si is more favorable than VivoSim Labs.
Profitability
This table compares VivoSim Labs and Quantum-Si’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| VivoSim Labs | -11,016.07% | -612.23% | -177.02% |
| Quantum-Si | -6,138.26% | -47.12% | -43.18% |
Insider and Institutional Ownership
8.2% of VivoSim Labs shares are held by institutional investors. Comparatively, 39.9% of Quantum-Si shares are held by institutional investors. 1.0% of VivoSim Labs shares are held by insiders. Comparatively, 22.0% of Quantum-Si shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Summary
Quantum-Si beats VivoSim Labs on 12 of the 14 factors compared between the two stocks.
About VivoSim Labs
Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat end-stage liver, life-threatening, and orphan diseases. The company was incorporated in 2007 and is headquartered in Solana Beach, California.
About Quantum-Si
Quantum-Si incorporated, a life sciences company, engages in the development of single-molecule detection platform to enable Next Generation Protein Sequencing (NGPS). The company's platform is comprised of the Platinum NGPS instrument; the Platinum Analysis Software service; and reagent kits and semiconductor chips for use with its instruments. It is used in protein identification, protein variants, antibody characterization, biomarker identification, and post translational modification analysis applications. The company was founded in 2013 is headquartered in Branford, Connecticut.
Receive News & Ratings for VivoSim Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VivoSim Labs and related companies with MarketBeat.com's FREE daily email newsletter.
